CYP19A1 and breast cancer: This cohort study evaluates the risk of hemorrhage requiring hospitalization or emergency department visits in patients with breast cancer taking direct oral anticoagulants (DOACs) concurrently with tamoxifen compared with an aromatase inhibitor.